An Early Phase 1 interventional study of LVIVO-TaVec400 product in Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD) and Progressive Multiple Sclerosis (PMS), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Withdrawn at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment
pipeline strategy change
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 11th largest by enrollment, is one of 5 that started in 2026, is one of 7 in phase 1, and was the 10th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–70
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–65
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–60
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–60
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 1
First in 2024; this study’s year is marked. 5 started in 2026.
Median enrollment 12 across the 11 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
6 of the studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07470151Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | 2026-11 |
| NCT06400537Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus | 2026-12 |
| NCT07031713Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySafety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE | 2026-12-31 |
| NCT07749430Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic Lupus Erythematosus | 2027-01-30 |
| NCT07339332Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
This is a prospective, single-arm, open-label dose-escalation and dose-expansion study, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the LVIVO-TaVec400, an in vivo chimeric antigen receptor (CAR) -T cell therapy in subjects with relapsed/refractory autoimmune diseases. The subject who meets the defined eligibility criteria will follow the sequential stages: screening, treatment (LVIVO-TaVec400 infusion) and follow-up (Up to 15 years).
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
Compared within Lupus Erythematosus, Systemic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical laboratory values meet criteria at screening visit.
r/r SLE:
Fulfill SLE conditions.
r/r IgG4-RD:
Progressive MS:
Presence of Cerebrospinal fluid (CSF) oligoclonal bands (OCBs) or elevated IgG Index at screening.
r/r MG:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dose escalation stage includes 4 dose level: DL1,DL2,DL3, DL4.
Biological: LVIVO-TaVec400 product
Each subject will be given a single-dose LVIVO-TaVec400 via intravenous infusion.
The incidence of Dose-limiting toxicity (DLT)
DLTs are severe adverse events refers to any untoward medical occurred in a subject participated in a clinical investigation, which has a causal relationship with the treatment and will limit the dose escalation.
Time frame: 28 days after LVIVO-TaVec400 infusion (Day 1)
The incidence, severity of Adverse events (AEs)
An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.
Time frame: Minimum 13 weeks after LVIVO-TaVec400 infusion (Day 1)
The incidence, severity of Treatment-related Adverse event (TRAE)
An treatment-related adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which has a causal relationship with the treatment.
Time frame: Maximum 15 years after LVIVO-TaVec400 infusion (Day 1)
Maximum concentration (Cmax) in peripheral blood
Maximum concentration (Cmax) in peripheral blood
Time frame: Maximun 5 years after LVIVO-TaVec400 infusion (Day 1)
Time of maximum concentration (Tmax) in peripheral blood
Time of maximum concentration (Tmax) in peripheral blood
Time frame: Maximum 5 years after LVIVO-TaVec400 infusion (Day 1)
Area under the concentration-time curve (AUC) in peripheral blood
Area under the concentration-time curve (AUC) in peripheral blood
Time frame: Maximum 5 years after LVIVO-TaVec400 infusion (Day 1)
Recommended Dose regimen finding
Determine the Recommended Dose regimen established through dose exploratory.
Time frame: Maximum 104 weeks after LVIVO-TaVec400 infusion (Day 1)
Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores from baseline for r/r SLE subjects
The SLEDAI-2K scale is a cumulative index used to assess disease activity across 24 different disease descriptors in patients with SLE. A total score ranges between 0 and 105, with a higher score representing a more significant degree of disease activity.
Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)
Change in IgG4-RD Response Index (IgG4-RD RI) from baseline for r/r IgG4-RD subjects
The IgG4-RD scale is a cumulative index used to assess disease activity across 25 different disease descriptions in patients with IgG4-RD. A total score ranges between 0 and 75, with a higher score representing a more significant degree of disease activity.
Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)
Change in Expanded Disability Status Scale (EDSS) scores from baseline for PMS subjects.
The EDSS is a scoring system used to quantify and monitor the progression of physical disability in patients with multiple sclerosis. The total score ranges from 0 to 10, with higher scores representing a worse outcome.
Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)
Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores from baseline for r/r MG subjects.
The MG-ADL is a patient-reported tool that quantifies the severity of myasthenia gravis symptoms based on daily functions. The total score ranges from 0 to 24, with higher scores representing a worse functional status.
Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)
Change in Quantitative Myasthenia Gravis (QMG) scores from baseline for r/r MG subjects.
The QMG is a standard clinical tool used to quantify the severity of myasthenia gravis through objective muscle testing. The total score ranges from 0 to 39, with higher scores representing a worse clinical status.
Time frame: Minimum 104 weeks after LVIVO-TaVec400 infusion (Day 1)
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2026 to primary completion in Sep 2026, 0 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Apr 2026 → Sep 2026, primary completion Sep 2028 → Sep 2026 and completion Sep 2041 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
pipeline strategy change
pipeline strategy change
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →